Jul. 3 at 12:09 AM
$BIIB
Are we finally in an uptrend? I hope.
Biogen (BIIB)'s LEQEMBI, Is currently approved for intravenous infusion administration.
The maintenance dose subcutaneous use version that can be administered at home has a tentative regulatory decision date issued by the FDA.
It is called the Prescription Drug User Fee Act (PDUFA) , it is on August 31, 2025.
Also remember that screening for Alzheimer's disease just got a lot easier because in May 16th 2025 the FDA approve the first and only blood screening test for Alzheimer's.
They have earnings on July 31st, 2025.
I'm expecting the price to bounce between the upper and lower BOLL bands in the next few weeks.
God speed
$VRTX $OGN $ABBV $BCRX